Does methotrexate treatment for ectopic pregnancy influence the patient's performance during a subsequent in vitro fertilization/embryo transfer cycle?

Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve

“…In fact, a recent publication showed clinical data confirming this empiric approach (26). Our research is of interest because no one has investigated this question elsewhere, taking into consideration not only the woman's reproductive future but also her ovarian reserve.…”

Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes

“…One additional study was excluded because none of the patients were undergoing ART [15]. Seven studies met all the inclusion criteria [16][17][18][19][20][21][22]. As shown in Table 1, five of the studies were retrospective cohort analyses and two were prospective observational studies [19,20].…”

“…Seven studies met all the inclusion criteria [16][17][18][19][20][21][22]. As shown in Table 1, five of the studies were retrospective cohort analyses and two were prospective observational studies [19,20]. All of the studies used a paired analysis of IVF cycles before and after MTX, but two studies also compared to a control group of patients who underwent salpingectomy [17,22].…”

A case of a methotrexate-resistant ectopic pregnancy in which dactinomycin was effective as a second-line chemotherapy

“…Recently, Orvieto et al reported that there is no influence of MTX treatment on the patient's performance in her immediate and subsequent IVF cycles (2). The current literature on EP includes multiple papers identifying predictors of MTX success (3).…”